HKSE - Delayed Quote HKD

Pharmaron Beijing Co., Ltd. (3759.HK)

8.780 -0.070 (-0.79%)
As of 9:33 AM GMT+8. Market Open.
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
11,537,996.315
11,537,996.315
10,266,288.180
7,443,769.724
5,133,596.759
Cost of Revenue
7,413,512.033
7,413,512.033
6,497,890.212
4,764,854.017
3,210,075.219
Gross Profit
4,124,484.282
4,124,484.282
3,768,397.968
2,678,915.707
1,923,521.540
Operating Expense
2,291,155.236
2,291,155.236
2,017,812.172
1,154,058.061
838,942.969
Operating Income
1,833,329.046
1,833,329.046
1,750,585.796
1,524,857.646
1,084,578.570
Net Non Operating Interest Income Expense
-152,258.214
-152,258.214
-134,633.824
-20,053.651
48,857.392
Pretax Income
1,837,886.586
1,837,886.586
1,666,391.305
1,910,995.517
1,319,369.459
Tax Provision
256,105.914
256,105.914
314,254.385
290,918.933
172,377.915
Net Income Common Stockholders
1,601,096.033
1,601,096.033
1,374,604.224
1,661,028.568
1,172,382.388
Basic EPS
0.90
0.90
0.78
0.93
0.66
Diluted EPS
0.90
0.90
0.77
0.91
0.66
Basic Average Shares
1,772,496.439
1,772,496.439
1,773,682.870
1,781,200.208
1,779,332.460
Diluted Average Shares
1,775,247.847
1,775,247.847
1,776,203.934
1,819,839.932
1,784,629.168
Total Operating Income as Reported
1,847,891.874
1,847,891.874
1,689,891.721
1,914,337.303
1,323,834.586
Rent Expense Supplemental
--
--
--
136,478.106
--
Total Expenses
9,704,667.269
9,704,667.269
8,515,702.384
5,918,912.079
4,049,018.189
Net Income from Continuing & Discontinued Operation
1,601,096.033
1,601,096.033
1,374,604.224
1,661,028.568
1,172,382.388
Normalized Income
1,660,244.566
1,660,244.566
1,418,400.819
1,750,289.378
1,095,292.219
Interest Income
33,542.987
33,542.987
35,213.061
64,406.935
74,064.426
Interest Expense
182,191.955
182,191.955
167,311.560
83,073.480
23,854.096
Net Interest Income
-152,258.214
-152,258.214
-134,633.824
-20,053.651
48,857.392
EBIT
2,020,078.541
2,020,078.541
1,833,702.865
1,994,068.997
1,343,223.555
EBITDA
2,947,249.159
2,947,249.159
2,529,882.703
2,491,989.430
1,718,385.212
Reconciled Cost of Revenue
7,413,512.033
7,413,512.033
6,497,890.212
4,764,854.017
3,210,075.219
Reconciled Depreciation
927,170.618
927,170.618
696,179.837
497,920.433
375,161.657
Net Income from Continuing Operation Net Minority Interest
1,601,096.033
1,601,096.033
1,374,604.224
1,661,028.568
1,172,382.388
Total Unusual Items Excluding Goodwill
-68,725.265
-68,725.265
-53,975.499
-105,289.473
88,675.818
Total Unusual Items
-68,725.265
-68,725.265
-53,975.499
-105,289.473
88,675.818
Normalized EBITDA
3,015,974.424
3,015,974.424
2,583,858.201
2,597,278.902
1,629,709.394
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-9,576.732
-9,576.732
-10,178.904
-16,028.662
11,585.650
12/31/2020 - 11/28/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

300404.SZ Boji Medical Technology Co.,Ltd.
7.55
+8.18%
 
6821.HK Asymchem Laboratories (Tianjin) Co., Ltd.
58.600
-1.01%
 
CSBR Champions Oncology, Inc.
5.03
-4.37%
 
9926.HK Akeso, Inc.
47.000
-0.95%
 
207940.KS Samsung Biologics Co.,Ltd.
777,000.00
-1.65%
 
1548.HK Genscript Biotech Corporation
10.640
-1.85%
 
9939.HK Kintor Pharmaceutical Limited
0.940
-1.06%
 
NAMS NewAmsterdam Pharma Company N.V.
21.80
+1.63%
 
2269.HK WuXi Biologics (Cayman) Inc.
12.660
-1.86%
 
SAR.L Sareum Holdings plc
30.50
-8.96%